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Abstract 
 
In order to better understand the needs of cancer patients and allocate resources, the 
Providence Alaska Cancer Center requested a needs assessment for an oncology focused 
patient centered medical home (PCMH). A PCMH allows for coordinated and 
comprehensive care through the use of a teamwork model that centers on the primary care 
physician. The Providence Alaska Cancer Center staff randomly selected the records of 200 
cancer patients between 2010 and 2011, using the cancer tumor registry. Data were analyzed 
to answer four specific questions that addressed the 1) presence of a Primary Care Physician 
(PCP), 2) number and type of comorbidities, 3) cancer diagnosis and 4) insurance status 
impacted emergency room utilization. Individuals tended to utilize the emergency room more 
if they 1) had a PCP, 2a) had three or more comorbidities, 2b) were diagnosed with 
hyperlipidemia, chronic obstructive pulmonary disease (COPD) or hypertension, 3) were 
diagnosed with an “other” cancer as opposed to breast, lung or gynecological cancers or 4) 
had federal insurance. These data in particular show expected trends such as patients who 
have more medical complications have higher emergency room utilization rates than patients 
with less complicated medical history and that certain comorbidities (hyperlipidemia, 
hypertension and chronic obstructive pulmonary disease) may be predictors of emergency 
room utilization. These trends may allow providers to create more specialized treatment and 
care plans for patients at greater risk of emergency room utilization.  
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Chapter 1: Introduction to Cancer and its Treatment 
Cancer 
Cancer is defined as the uncontrolled growth of cells within the body, and is often 
represented by solid tissue malignant tumors. There are several risk factors associated with 
cancer such as smoking, diabetes, diet, exposure to ultra violet radiation, and alcohol use 
(Houde, Melillo, & Holmes, 2012). By definition, malignant tumors are serious and 
dangerous to a person’s health and well-being, as they have the ability to invade and destroy 
nearby tissue, and may have the capacity to spread (i.e., metastasize) to other parts of the 
body or recur following treatment. Cancers are generally labeled to reflect the anatomical 
sites from which they originate, for instance colon cancer, breast cancer, lung cancer, liver 
cancer and skin cancer (Panno, 2005). Within anatomical sites, there are different tissue types 
or variations in cell differentiation that may further modify the classification of the cancer. 
For example, skin cancer can consist of basal cells, squamous cells or melanocytes. 
Depending on the cell type, the tumor will exhibit different characteristics.  
Typically, cancer is not the only disease to affect cancer patients. Cancer can be 
accompanied by a host of medical and psychological comorbidities that may have existed 
before the onset of cancer or come after, as they may be secondary to the disease and/or its 
treatment. Examples of comorbidities include arthritis, asthma, congestive heart failure 
(CHF), chronic obstructive pulmonary disease (COPD), depression, diabetes, hypertension, 
injuries, and renal failure (Hudson et al., 2012). By 2030, an estimated 60% of survivors are 
expected to be over the age of 65, resulting in an increased likelihood for significant 
comorbidities and further leading to the need for proper comprehensive patient care (Pal & 
Hurria, 2010). The cancer survivor population in the U.S. was an estimated 11.9 million 
people in 2008 (Centers for Disease Control and Prevention, 2014a). By 2050, it is expected 
that the number of cancer survivors will surpass the number of new cancer cases. This shift 
in patient populations will increase the need for medical and other specialty providers who 
can treat the diverse issues cancer patients experience and require a more efficient model of 
patient care, including aftercare (Hudson et al., 2012). 
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Cancer Treatment 
Cancer care is a life changing experience. Cancer care is made up of a complex set of 
calculations and processes that do not always occur congruently. Cancer treatment can be 
long and stressful, and may be complicated by the presence of many of the aforementioned 
comorbidities. Cancer treatment consists of several treatment modalities that may be used 
individually or in conjunction with each other. Treatment options include radiation, surgery, 
chemotherapy, and targeted therapy (American Cancer Society, 2015). Patients who undergo 
treatment for cancer may experience a whole host of side effects associated with therapy such 
as pain, nausea, vomiting, fatigue, anemia, infection, and depression (American Cancer 
Society, 2015). 
Cancer patients can experience concerns for their physical, mental, and financial 
health. Cancer patients will face unfamiliar experiences and develop new habits that may 
include deciding on the appropriate cancer therapy, different diets and lifestyles, and learning 
about medical treatments and terminology (Panno, 2005). Even after finishing treatment for 
his/her cancer, the patient will require a follow-up treatment or survivorship plan. This 
survivorship plan is typically based on the staging and type of cancer, the treatment received, 
the risk for recurrence or additional cancers and any comorbidities the patient may have. 
Many patients will have annual check-ups for several years and even then the risk of 
recurrence still exists (National Cancer Institute, 2010). How patients adapt to their new 
reality is highly variable. However, some of the best patient outcomes can be attributed to 
active participation from the patient in managing their cancer treatment and follow-up care, 
i.e. patient activation (Blinder et al., 2013). Given the diverse needs of cancer patients, it is 
necessary for comprehensive cancer care to address the biological and psychosocial concerns 
of cancer patients.  
In addition to the routine oncology treatments, emergency services may play an 
important role for cancer patients. Due to compromised immune systems resulting from 
cancer treatment and the increase in side effects from more aggressive treatment options 
currently available, having access to immediate care is often critical (Rovere et al., 2012). 
Oncologic emergencies that require treatment in an emergency setting can occur over several 
months or happen in several hours. Cancer emergencies can be categorized as metabolic, 
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hematologic, structural, or side effects to treatment (Sadik et al., 2014).  The most common 
reasons cancer patients visit the emergency room is to treat the side effects of pain or a high 
fever (Raji, 2009). In a study in Brazil of the common profile of cancer patients who seek 
treatment at the emergency room, Rovere et al. (2012) found that patients with urological, 
breast, gastrointestinal and lung cancers had greater demand for emergency room care.  
Cancer patients face a plethora of complications, including complications that may 
not seem life threatening for a healthy patient. For a cancer patient who is currently 
undergoing chemotherapy and is therefore immunocompromised, a fever of 101 degrees 
Fahrenheit may be reason enough to visit the emergency room (Tannebaum et al., 2014). 
Cancer patients are typically informed to be aware of certain signs and symptoms such as 
nausea, vomiting, severe diarrhea, bleeding, and shortness of breath. If the patient does 
experience these side effects during the day the solution may be as simple as contacting their 
oncologist or primary care provider if they have one. Complications after hours may leave 
the patient with no choice but to use the emergency room (Tannebaum et al., 2014). 
Depending on the situation the patient may not need to utilize the emergency room if 
appropriate access to a primary care provider is available, or if the patient has been well 
educated about what to do in case these signs and symptoms occur (Tannebaum et al., 2014). 
The benefits of emergency room usage are that it is available 24 hours a day and 7 
days a week without appointment. There is a greater amount of resources available such as 
hospital staff, lab, supply, and pharmacy (American College of Emergency Physicians, 
2014). Unfortunately these same benefits can be drains on hospital resources if patients 
utilize the emergency room too much (Tannebaum et al., 2014). Rovere et al. (2012) suggest 
the need for improved primary care and oncology clinic services in order to meet the 
demands of oncology patient care so that unnecessary visits to the emergency room could be 
reduced and/or prevented.  
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Chapter 2: Introduction to the Patient Centered Medical Home Model 
Patient Centered Medical Home 
The Patient Centered Medical Home (PCMH) model was first developed in the 
United States in the 1960s to create a system that fostered comprehensive care and shared 
decision-making between the patient, primary care providers, other providers, and the 
patient’s family (American Hospital Association, 2010). Patient centered medical homes 
were originally created to help children with special healthcare needs in the community. In 
2004, the American Academy of Family Physicians adopted the PCMH model. Currently the 
PCMH model is being adapted to different areas of healthcare such as oncology (Houde et 
al., 2012). The PCMH model helps place a priority on managing the health of patients and 
increasing access to healthcare (American Hospital Association, 2010). 
A PCMH model is a provider-directed medical practice in which the patient’s 
personal provider takes the leading role in a team care approach; the primary care provider is 
aware of the majority of medical decisions, while responsibility is shared among the team for 
that patient. Having a primary care provider means the patient has a medical provider who 
understands his/her individual needs. It allows the patient to build a rapport with that 
provider, who is the first point of contact for the patient when a medical necessity occurs 
(Houde et al., 2012).  
Some of the numerous benefits of PCMH models include use of electronic medical 
records (EMRs) to allow better record keeping and communication between providers, 
increased coordinated care, use of registries to take a population-based approach to care, 
enhanced access, increased data collection, increased patient satisfaction, whole-person 
orientation, and improved quality and safety (Houde et al., 2012). Patient Centered Medical 
Homes also provide a place for current cutting edge technological healthcare applications 
such as tele-health and mobile health (Hudson et al., 2014). This use of technology could be 
beneficial by reducing healthcare costs. Finally, PCMH models relate well to the current 
drive for new payment models to replace the current fee-for-service model and its inability to 
adapt to comprehensive patient-centered care (Houde et al., 2012). 
The PCMH model can increase quality and safety by supporting the use of the most 
up-to-date evidence-based approaches to patient care (Pal & Hurria, 2010).  Patient Centered 
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Medical Homes can support a wide variety of patients with a range of diseases. These 
diseases range from chronic illnesses to infectious diseases. Patient Centered Medical 
Homes, in general, provide a positive effect on outcomes by allowing for better coordination 
among practitioners treating patients, and by promoting access and active participation by the 
patient within the healthcare team (Pal & Hurria, 2010). This effect occurs through better 
communication with patients and a better comprehension of their needs, resulting in better 
patient outcomes and increased patient satisfaction. Clinical staff are better trained and more 
engaged in creating efficiencies through team based care. Responsibilities are shared across 
the entire medical team, which may include nutritionists, behavioral health specialists, and 
exercise specialists, who are likely to have more targeted and current knowledge of certain 
areas of healthcare than the physician (Sprandio, 2012).  
When discussing the benefits of a PCMH model, it is important to discuss the benefits 
from an emergency room stand point, which includes certain diagnostic tests being 
performed at the primary care provider’s office instead of the emergency room, which may 
cut down on the cost of expensive or unnecessary hospital/ER-based testing (Sprandio, 
2012). Also, current research has shown that patients who have seen their primary care 
provider within the last year are less likely to visit the ER than patients who have not seen 
their PCP within the last year (Chaiyachati et al., 2014). 
While the PCMH model offers a variety of benefits, there are drawbacks to the 
PCMH model such as costs, training, and time (Jackson et al., 2013). One of the greatest 
challenges facing practices wanting to switch over to a PCMH model is implementation, 
since the transformation process doesn’t occur over weeks but rather years; it can be difficult 
to track patient and practice progress if the proper monitoring assessments are not in place. 
Other implementation challenges include there being no one blueprint for the transformation 
process and comparing medical homes can be difficult due to the different characteristics of 
patient populations (Jackson et al., 2013). 
Patient Centered Medical Homes for Oncology Patients 
The application of a PCMH model for oncology patients is limited currently. A 
literature search revealed just a handful of oncology centers using a PCMH model (Sprandio, 
2012).  Since it is apparent that a PCMH model can improve patient satisfaction and health 
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outcomes in family medicine, it is important to explore the positive gains PCMH models can 
also have for cancer patients.   Implementation of a comprehensive care model for cancer 
care, such as a PCMH model, could provide patients with better cancer treatment, overall 
care, and improved survivorship (Sprandio, 2012). A PCMH model is one way the 
complexities of cancer treatment and survivorship care can be streamlined for patients. The 
desire and need to coordinate cancer treatment and treatment of the host of comorbidities 
associated with cancer and cancer treatment is growing in the United States (Sprandio, 2012). 
Patient Centered Medical Homes have been shown to help empower the patient by making 
the patient part of the healthcare team (Sprandio, 2012). The PCMH model may also provide 
additional benefits of increased efficiencies and lower costs.  
An example of a need for coordinated cancer care is in breast cancer patients, 
especially among circumpolar populations (Young & Bjerregaard, 2008). In the United 
States, breast cancer survivors make up 25% of the entire cancer survivor population, making 
breast cancer patients an ideal population to study for developing better patient care methods. 
Research has shown that breast cancer patients feel that there is currently a lack of 
communication between oncologists and Primary Care Physicians (PCPs) (Blinder et al., 
2013). Over half of PCPs feel that they receive insufficient information about their patients’ 
cancer diagnoses and treatments (Blinder et al., 2013). The PCMH model offers a model of 
coordinated care that allows for easier communication between PCPs and oncologists as well 
as other specialists who make up the comprehensive care team.  
While there are many descriptive studies available about PCMH models, more 
analytical studies are less common. The implementation of PCMH models in an oncology 
setting has only recently taken hold in the healthcare industry, in part due to recent healthcare 
reform; therefore, the research is still in its early phases. More quantitative data analysis is 
necessary to understand the impacts and determine the next questions that need to be asked 
about the potential benefits of the PCMH model and its application to oncological care.  
While PCMH models offer a host of potential benefits such as increased patient 
health and reduced costs, a major challenge that PCMH models face, is the initial effort and 
costs of converting to a PCMH model (Weiss, 2013). Many of the upfront costs include the 
purchase and implementation of an electronic health record, conducting patient satisfaction 
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surveys, and training employees to engage in team-based care and support patients in proper 
self-care (Weiss, 2013). 
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Chapter 3: Treatment of Cancer in Alaska 
Alaska is a vast state with varying climate and geographical challenges. The 
remoteness of the state makes access to nutritious food difficult for many Alaskans, 
especially in rural areas, which increases the risk of developing diabetes, a known risk factor 
for cancer (Hudson et al., 2012). Alaskans also have increased rates of alcohol use, another 
risk factor for cancer, with Alaska having twice the rate of alcohol abuse and dependence 
compared to the national average (Alaska Department of Health and Social Services, 2012a). 
Due to increased risk factors, Alaskans have shown to be at increased risk of developing 
cancer (Alaska Department of Health and Social Services, 2012a).  
Across Alaska, 2,136 cancer cases were diagnosed in 2012, with approximately 
38,000 new cancer cases being diagnosed from 1996 to 2012  (Alaska Department of Health 
and Social Services, 2014).  Cancer has continued to be a leading cause of death among 
Alaskans since 1993 (Alaska Department of Health and Social Services, 2012b). 
Approximately 25% of all Alaska deaths in 2009 were caused by cancer. The most common 
cancers diagnosed in Alaska were breast, prostate, lung, and colorectal (Alaska Department 
of Health and Social Services, 2012b). Also, cancer rates are not uniform across the state; 
instead, there are disparities in both the incidence and mortality of cancer between Alaska 
Natives and non-Alaska Natives, with Alaska Natives being more likely to be diagnosed with 
cancer and die following the diagnosis (White et al., 2014). While cancer treatment is a 
needed focus, there is also an increased need for cancer survivorship programs in the state of 
Alaska as cancer survival rates continue to increase (Alaska Department of Health and Social 
Services, 2012b). 
The Providence Alaska Cancer Center 
Providence Health and Services, as one of the largest providers of healthcare in 
Alaska, has a responsibility to be responsive to the growing needs of cancer patients in the 
state of Alaska. The Providence Alaska Cancer Center (PACC) opened in 2007 and its cancer 
program is accredited by the Commission on Cancer (COC). It provides numerous ancillary 
services on-site for cancer patients, including navigation services, genetic counseling, 
oncology-focused physical rehabilitation, wig and prosthesis assistance, financial services 
assistance, distress screening, a dietary consultative service, a healing arts program, and the 
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Susan Butcher Family Center. In addition, PACC supports a clinical trials department, a 
tumor registry, multiple tumor boards, and the hospital medical staff’s cancer committee. A 
survivorship program is also in development at the PACC. A survivorship program helps 
patients transition from acute cancer care treatment with education, monitoring of long-term 
side effects and referrals to recovery services. These services include smoking cessation, 
physical therapy and rehabilitation, nutrition, psychosocial support and counseling, social 
work and fertility, among others (Providence Health and Services, 2014).  
Patient care on site is limited to pediatric oncology, an outpatient the infusion center 
and radiation oncology, with radiation therapy being provided in partnership with an 
independent physicians group. Other independent but closely aligned cancer-related 
physician offices in the same building include a medical hematology-oncology group, a 
gynecologic oncology group, and several private surgical offices. Cancer treatment for 
patients is primarily directed by independent oncologists, radiation oncologists and/or 
surgeons. Survivorship care is variable and may or may not stay under the direction of the 
oncologist, radiation oncologist or surgeon. Currently, there is no formal program or 
structure in place that enhances the coordinated care of a patient. There are referrals from 
primary care providers to oncology specialists and some referrals from oncology specialists 
to primary care doctors, but primary care is not part of the Providence Cancer Center 
program. Patients are either self-selected or referred from oncology providers to navigation, 
genetic counseling or oncology rehabilitation. Having a PCMH model might make the 
selection process less random or biased to certain physicians or patients that are aware of 
services, and help to ensure that cancer patients have a primary care provider. This project is 
looking at the implementation of a PCMH model because of the need for improved 
coordination of patient services inside and outside of the cancer center, with primary care 
included. 
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Chapter 4: Study Goals, Rationale, Research Questions and Hypotheses  
Study Goals  
Provision of a PCMH model at the Providence Alaska Cancer Center is of potential 
interest to the Providence Alaska Medical Center, healthcare leaders, and public and private 
payers, given that PCMH models have the potential to provide improved coordinated 
comprehensive patient care, increased patient satisfaction, cost savings and improved 
management of the predicted increase in survivorship (Hudson et al., 2012).  
The Providence Alaska Cancer Center medical director, Dr. Thomas Mego, has 
expressed a desire to explore the possibility of implementing a PCMH model within the 
PACC. Thus, this research project sought to answer several questions about the need for, and 
potential benefits of, a PCMH model at the Providence Alaska Cancer Center. In addition, 
Dr. Mego, and Ms. Marian Jones (Administrative Director of the PACC) will use the data 
collected through this research project to improve the quality of care for patients that are 
touched by the Providence Alaska Cancer Center. 
 Specifically, the aim of this project is to better understand the healthcare needs of 
cancer patients in the PAMC patient population, with a focus on comorbidities, and assess for 
any gaps in the ability of patients to access the care necessary to meet those needs. 
Depending on what the data illustrate, further research projects may be needed to determine 
how to implement an oncology PCMH model, or other form of coordinated care, and what 
other resources should be available to cancer patients such as mental health services or 
weight loss services, etc. 
Conceptual Framework 
The Precede-Proceed Model is an excellent model for analyzing a health situation, 
understanding it, and designing an effective intervention program. An example of the 
Precede-Proceed Model can be seen in Appendix A. The Precede-Proceed Model is often 
thought of as a road map and it provides a structure for applying theories and concepts 
systematically for planning and evaluating health behavior modification through risk (Glanz, 
Rimer, & Viswanath, 2008). The eight phase Precede-Proceed planning model consists of 
four planning phases, one implementation phase, and three evaluation phases. The first four 
phases can further be classified as the Precede phases and the latter four as Proceed phases. 
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The Precede phases are designed as planning and assessment phases, while the Proceed 
phases focus on implementation and evaluation of the desired outcome. Together these 
phases help researchers focus on the analysis of outcomes by allowing researchers to work 
backwards to help identify strategies for achieving those objectives (Glanz, Rimer, & 
Viswanath, 2008). Another benefit of the Precede-Proceed Model is that it helps weigh the 
costs against the benefits of certain health programs, which is important for any healthcare 
organization. Through the use of a multi-phasic Precede-Proceed Model, a better 
understanding of hospital utilization, comorbidities, and how use of general providers affects 
cancer patients’ health outcomes can be gained.  
In this model, we seek to better understand Phase Three. Phase three focuses on the 
behavioral and environmental factors of the population (Glanz, Rimer & Viswanath, 2008). 
For this project, the representative population is cancer patients who have been treated at the 
Providence Alaska Medical Center (PAMC). Several factors relate to their health needs 
including: comorbidities, type of cancer, insurance type, having a general provider, and 
hospital/emergency department utilization. By better understanding these factors and this 
population, new models of patient care can be used to improve patient outcomes. 
Study Rationale 
Several factors related to the healthcare of cancer patients, and possibly with linkage 
to a coordinated care mode like a PCMH, were selected based on recommendations from the 
PACC medical director. The characterization of these factors will help determine the need for 
a PCMH model at the Providence Alaska Cancer Center as well as some of the specific focus 
areas of a PCMH model. Specifically, this study focused on examining which patient factors 
influence emergency room utilization. Initially, this project planned to review several types 
of hospital encounters including emergency room admission, hospital admission, or hospital 
readmissions; however, only emergency room admissions were able to be collected based on 
how information was labeled within the medical record. Hospital admissions and 
readmissions were not collected or examined because of the difficulty of determining if a 
specific service was inpatient or outpatient without significant time and exploration of each 
patient’s medical chart.  
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Regardless of this limitation in medical treatment usage, valuable information can 
still be gleaned from examining just emergency room utilization. By understanding which 
factors are associated with increased emergency room utilization (which can be an expensive 
and non-preferable mechanism for regular medical care), recommendations can be made in 
order to effectively identify and support patients who have high emergency room utilization, 
and create a PCMH model that is sensitive to the needs of higher risk patients.  
The factors that were selected by the medical director for examination included 1) 
whether or not a cancer patient has a documented PCP, 2) the number and types of 
comorbidities affecting cancer patients, 3) type of cancer diagnosis, and 4) type of patient 
insurance.  
 The presence of a current PCP was a factor to consider. Whether a patient does or 
does not have a current PCP is important in understanding the health status of a patient.  How 
recently a patient has visited their PCP can tell a lot about a patient’s habits as well as how 
thorough their current medical history may be (Hudson et al., 2012). Patients who do not 
have a current PCP, and may not have had one for some time, will most likely not have a 
current medical history and they may have underlying untreated chronic conditions such as 
arthritis, cardiovascular disease, obesity, and diabetes (Hudson et al., 2012). A lack of a PCP 
and unmanaged comorbidities may result in unnecessary ER visits and admissions. 
 The risk of cancer increases with age, as does the risk of developing comorbidities 
(Pal & Hurria, 2010). Cancer patients 55-64 years old were found to have an average of 2.9 
comorbidities. Comorbidities include arthritis, asthma, congestive heart failure, chronic 
obstructive pulmonary disease, depression, diabetes, hypertension, injuries, pain and renal 
failure (Pal & Hurria, 2010). The number of comorbidities may affect the diagnosis, 
treatment and prognosis of cancer. As an example, patients who were treated using 
neoadjuvant hormone therapy followed by radiation for localized prostate cancer were found 
to have an increased risk of mortality if they two of the three risk factors which included 
coronary artery disease, congestive heart failure (CHF), or prior myocardial infarction. If the 
patient only had one cardiovascular disease risk factor, they had no increased risk for 
mortality under the same treatment (Pal & Hurria, 2010). Assessing for comorbidities in the 
cancer patient population at the Providence Alaska Cancer Center and how they relate to ER 
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visits was critical to characterizing the need for a PCMH model of care. The number of 
comorbidities a cancer patient has may play a role in ER usage. By examining the number 
and types of comorbidities a cancer patient has, a more accurate assessment of the patients’ 
needs may be developed allowing for better-coordinated care during and after cancer 
treatment (Sprandio, 2012). 
Type of cancer was selected for examination because of the diversity in how type of 
cancer can impact the patient’s health and medical treatment. For instance, different types of 
cancer require different treatments and follow-up plans, with variable risk for treatment 
related morbidity (side effects) and need for emergent care (Sprandio, 2012). Also, there may 
be a relationship between different cancer types (e.g., breast cancer versus colon cancer) any 
unique types of comorbidities that may also impact how patients utilize medical services 
such as the ER. These comorbidities may be caused by treatment or may have been already 
present (Pal & Hurria, 2010).  
 Insurance status and type was the final variable selected for examination, as insurance 
type may be related to socioeconomic status and overall health and wellbeing, as well as 
ability to pay for care. Insurance type and status was selected to determine if there was a 
difference between patients with public insurance (Medicare/Medicaid/Veteran’s Affairs) 
and patients with private insurance. Medicare is a social insurance provided by the federal 
government (Centers for Medicare & Medicaid Services, 2015). Medicare is used to cover 
senior citizens and certain disabled individuals. Medicaid is an insurance program, which 
covers very low-income children and their families (Centers for Medicare & Medicaid 
Services, 2015). Both the federal government and state government jointly fund Medicaid. 
This variable was important to help establish a better understanding of how cancer patients 
with different insurance types may utilize hospital resources differently and may allow the 
Providence Alaska Medical Center to better communicate with the State of Alaska as well as 
private insurance companies to help promote preventative efforts in order to help reduce ER 
usage.   
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Research Questions 
Research questions were developed based on the information presented above 
regarding factors of cancer patients that could impact hospital usage. The four research 
questions were used to guide the research project, and included: 
 
1) Is there is a difference in emergency room usage between cancer patients without 
general providers and with general providers? 
 
2) a) Does the number of patient comorbidities impact emergency room usage? 
b) Which specific comorbidities are the best predictors of emergency room  
 usage? 
 
3) Does type of cancer impact emergency room usage? 
 
4) Does type of insurance (private versus public) impact emergency room usage? 
Hypotheses 
 Hypotheses were generated based on the selected research questions in order to guide 
data analysis and interpretation. The first two hypotheses are directional, with a specific type 
of relationship being predicted between the grouping variable and the dependent variable of 
emergency room utilization, while the final three hypotheses are non-directional and instead 
predict that a difference will exist between the factors with regard to the level of emergency 
room utilization.  
 
Hypothesis 1: Patients with general providers will utilize the ER less than patients who do 
not have a general provider.  
 
Hypothesis 2a: Patients who have three or more comorbidities will utilize the emergency 
room more than patients with less than three comorbidities. 
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Three comorbidities was used as a cutoff for this research question based on previous 
research by Pal and Hurria (2010) that found that cancer patients above age 55 had on 
average 2.9 comorbidities. 
 
Hypothesis 2b: There will be a difference in emergency room utilization depending upon type 
of comorbidity present. 
 
Hypothesis 3: There will be a difference in emergency room utilization depending on the type 
of cancer diagnosis.  
 
Hypothesis 4: There will be a difference in emergency room utilization for patients who have 
private insurance versus patients who have insurance through the public system.  
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Chapter 5: Methods 
Timeline 
 A schedule was created in order to ensure the project was completed in a timely 
manner. Tasks included proposal development and approval; Institutional Review Board 
(IRB) credentialing and approval (through both UAA IRB and the Providence Research 
IRB); data collection, data analysis, and report and presentation development. Modifications 
to the timeline were made following greater than anticipated times in terms of approval from 
the UAA IRB board and collection of data by the research volunteer at the Providence 
Alaska Cancer Center. The following Table 1 includes both the initial projected completion 
dates for various project tasks, as well as the actual completion dates for these tasks. 
Table 1. Project practicum projected and completed timeline. 
Task 
Projected 
Completion Date 
Actual Completion 
Date 
Initial Project Draft to MPH Committee November 1, 2014 October 16, 2014 
Project Submission to UAA IRB 
Early November 
2014 
December 19, 2014 
Revisions made based on UAA IRB 
feedback/Receive IRB approval 
End of November 
2014 
March 20, 2015 
Approved Protocol Submitted to 
Providence Research IRB 
December 2014 March 20, 2015 
Approval from Providence Research IRB December 2014 March 24, 2015 
Data Collection Begins December 2014 May 2015 
Data Collection Ends January 2015 June 2015 
Data Analysis January 2015 July 2015 
Project Practicum Presentation February 2015 September 2015 
Written Report Presented to MPH 
Committee 
March 2015 September 2015 
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Protection of Human Subjects 
Data were protected in conjunction with the Providence Alaska Medical Center’s risk 
management and clinical trials departments, and per approved UAA IRB protocol. See 
Appendix B for the IRB approval letter and Appendix C for the letter of approval from the 
Providence Research IRB for this project. Data were stored on a password-protected 
computer that remained at Providence. The raw data are only accessible to Dr. Mego. The 
Principal Investigator only had access to the de-identified data. Data will be stored for up to 
10 years.  
Based on the protocols, several considerations for the protection of human subjects in 
this archival study were made. The sample selected from the tumor registry was random. No 
personal identifiers were used in the presentation of the data. No interaction was made with 
patients directly nor will care or treatment of the current study patients be modified due to 
this research project. Patients of PAMC signed a consent form upon admission (see 
Appendix E) indicating that information may be used for Providence Health and Services 
Business Operations. 
Data Collection  
Data for this project were collected in a multi-stage process. The first stage included 
random sample selection. This stage utilized the tumor registry database for the Providence 
Alaska Cancer Center. Tumor registry staff randomly pulled 200 cancer patients that were 
treated at Providence between 2010 and 2011. In the initial power analysis, it was determined 
that two hundred patients were required to demonstrate a moderate effect. Using G-power, it 
was found that one-hundred and twenty-eight cancer patients was the minimum population 
required to run the statistical tests for the data analysis. Realizing that some patient charts 
may not have all the data the research project was interested in, Dr. Mego and the Principal 
Investigator determined 200 patients to be a reasonable number to establish statistically 
relevant and useful data. 
 The tumor registry data was accessed through Metriq database and included 
information such as the cancer type for each patient selected. The second stage of data 
collection was the retrieval of patient demographic information as well as medical 
information that was pertinent to research questions. This information was housed within the 
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Providence Health Information System (Epic). Demographic data that was collected included 
age, gender and racial/ethnic group. Medical information that was pulled included 1) patient 
comorbidities, 2) emergency room encounters, 3) type of insurance, 4) presence of Primary 
Care Physician (PCP), and 5) type of cancer. For the comorbidities data, a literature review 
done by Pal and Hurria (2010) identified the most common comorbidities associated with 
cancer patients. From this literature, Dr. Mego and the Principal Investigator selected the ten 
comorbidities that were examined for this study including: arthritis, asthma, congestive heart 
failure, chronic obstructive pulmonary disease, depression, diabetes, hypertension, injuries, 
pain and renal failure. This data included searching for Current Procedural Terminology 
(CPT) codes related to the 200 patients’ comorbidities and hospital encounters.    
 A research volunteer from the Providence Alaska Cancer Center manually collected 
the data by reviewing the charts of the patients who were randomly selected. This volunteer 
was trained with respect to proper protocols for data collection and protection, and only 
provided a de-identified Excel spreadsheet to the Principal Investigator for analysis (See 
Appendix E). 
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Chapter 6: Sample Demographics and Description 
Demographics 
 A random sample of 200 patients from the Providence Alaska Cancer Center tumor 
registry was selected out of the approximately 1,200 cancer patients who received services at 
PAMC in 2011. The mean age of participants was 61.95 (SD = 15.6), ranging from 4 to 94 
years old. The sample was primarily female (65%) and Caucasian (83.5%). A small segment 
of the sample did not have their racial group documented within the medical record. See 
Table 2 for a demographic breakdown of the sample by age, race and gender. The sample 
appeared to have more females than males; this difference is likely due to the cancer sites 
prevalent at PAMC.  
Table 2. Sample demographics of age, race and gender  
Demographic Variable Sample (N = 200) 
Age 61.95 (15.6) 
Gender  
Female 65% 
Male 35% 
Race  
Caucasian 83.5% 
African American 6.0% 
Asian 4.5% 
Alaska Native/American 
Indian 
3.5% 
Hispanic** 1.5% 
Unknown/Other/Multiracial 1.0% 
Primary Care Providers 
 Each patient’s medical record indicated whether or not the patient had a Primary Care 
Physician (PCP) and provided the name of the PCP. The majority of the sample did have a 
primary care physician (84.5%).  
Comorbidities 
 Out of the possible 10 comorbidities that were examined, the number of documented 
comorbidities in individual patients ranged from 0 to 6, with an average of 1.33 (SD – 1.4) 
comorbidities. When breaking down the number of comorbidities into categories (i.e., less 
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than three comorbidities or three or more comorbidities), approximately 80.5% of the sample 
had less than three comorbidities, illustrating that only a fifth of the sample was placed into a 
higher risk group based on the number of comorbidities. The specific type of comorbidities 
varied in prevalence, with hypertension (40.5%), depression (16.5%), diabetes (15.5%) and 
hyperlipidemia (15%) being the most common types of comorbidities associated with cancer 
patients in this sample. Three of these comorbidities are linked to increased risk of 
cardiovascular disease, and hypertension has been shown to be twice as prevalent in patients 
with diabetes than patients without diabetes (American Heart Association, 2012). The least 
common comorbidity was injuries, with 0 percent of the sample having a documented injury 
in their medical chart. See Figure 1 for a graphic display of the percentage of patients having 
each type of comorbidity.  
 
 
Figure 1. Sample comorbidity types 
Cancer Diagnosis 
There was diversity in sample patient cancer diagnosis. Table 3 includes the 
percentage of the sample that was diagnosed within each cancer category in the order of most 
represented in the sample, to least represented. National rates from the National Institute of 
Cancer of new cancer cases by cancer type diagnosed between 2008 and 2012 are also 
included for comparison, although some cancer types did not have rates displayed.  The top 
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three most common cancer diagnoses included breast cancer (27%), lung cancer (13%) and 
gynecological cancers such as ovarian, uterine, fallopian and endometrial cancers (12%). A 
small portion of the sample (2%) had an unknown cancer diagnosis according to 
documentation within the electronic medical record, possibly based on difficulty determining 
the site of original cancer that had metastasized.  
 
Table 3. Sample cancer diagnosis percentages vs. national 
Cancer Diagnosis  Sample % National %* 
Breast 27.0% 14% 
Lung 13.0% 13.3% 
Gynecological** 12.0% 5.7% 
Brain 6.5% 1.4% 
Large Intestine/Rectum 5.0% 8.0% 
Liver/Bile Duct 4.5% 2.2% 
Bladder 4.0% 4.5% 
Thyroid 4.0% 3.8% 
Bone 3.5% 0.2% 
Kidney 3.0% 3.7% 
Pancreas 3.0% 3.0% 
Prostate 3.0% 13.3% 
Lymphoma 2.5% 4.8% 
Oral 2.0% 2.8% 
Unknown 2.0% - 
Skin 1.5% 4.5% 
Soft Tissue 1.5% unknown 
Small Intestine 1.0% 0.6% 
Stomach 0.5% 1.5% 
Thoracic 0.5% unknown 
*percentage of new cancer cases in # that are diagnosed based on data from the National Cancer Institute: 
http://seer.cancer.gov/statfacts/more.html 
** includes ovarian, uterus, fallopian tube, vulvar and cervical 
Insurance 
 Information in the patient medical records indicated the patient’s insurance status and 
documented which insurance the patient utilizes. A wide variety of insurances were used, 
both commercial (i.e. Premera Blue Cross, Wells Fargo, Aetna, Meritain Health, etc.) and 
public insurance programs (i.e., Medicare, Medicaid, Veterans Affairs (VA) insurance). 
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Several patients had double coverage of insurance, and thus were coded for insurance 
category (commercial versus public) based on their primary insurance.  There were roughly 
equal rates of patients with commercial (39.5%) and public (42%) primary insurance. The 
most common type of commercial insurance was Premera Blue Cross Blue Shield while the 
most common type of public insurance was Medicare. The remaining percentage of the 
sample (18.5%) had either an unknown insurance status, were self-pay or had services 
provided through charity or Project Access, a provider network that helps low income 
patients get needed specialty medical care (Anchorage Project Access, n.d.). See Figure 2 for 
a graphic display of the insurance status of the sample. 
 
 
Figure 2: Insurance status 
 
Emergency Room Utilization 
 A records review was performed for each patient in the sample, where the research 
assistant compiling the data counted the number of Emergency Room visits that were 
documented in a patient’s chart from the time of their cancer diagnosis. Emergency Room 
visits ranged from 0 to 11 visits, with a mean of 1.4 (SD = 2.1). The results were positively 
skewed, with 45 percent of the sample having no emergency room visits. See Figure 3 for a 
graphic display of the number of patients by Emergency Room visits.  
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Figure 3. Number of emergency room visits 
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Chapter 7: Results and Discussion 
Results 
 Primary Care Provider 
The first question was to determine whether or not there is a difference in emergency 
room (ER) utilization (i.e. number of ER visits) by cancer patients with primary care 
providers and cancer patients without primary care providers. To explore this question, an 
independent samples t-test, with an independent variable of presence of primary care 
provider and a dependent variable of number of emergency room visits, was conducted. The 
independent samples t-test was significant, t (77.83) = 3.21, p = .002, with individuals who 
have a primary care physician having a significantly higher mean number of emergency 
room visits (M = 1.53, SD = 2.1) than patients who do not have a primary care physician (M 
= 0.7, SD = 1.1). See Figure 4 for a graphic display of the mean differences. Emergency 
room utilization rates for individuals with a PCP ranges from 0 to 11 visits, while those 
without a PCP ranges from 0 to 4.  
 
*statistically significant differences between the groups at the p <.05 level 
Figure 4. Mean emergency room utilization by primary care physician status 
Comorbidities 
The second question was whether cancer patients who have three or more 
comorbidities differ in ER utilization from cancer patients with less than three comorbidities. 
An independent samples t-test was used to explore this question, with an independent 
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variable of number of comorbidities (with participants being grouped into those who have 
equal or greater than average number of comorbidities and those who have less than average 
number of comorbidities according to Pal and Hurria’s (2010) research and a dependent 
variable of number of emergency room encounters. The independent samples t-test was 
significant, t(48.96) = -2.4, p = .014, with individuals who have three or more comorbidities 
having a significantly higher mean number of emergency room visits (M = 2.28, SD = 2.5) 
than patients who has less than three comorbidities (M = 1.19, SD = 1.9). See Figure 5 for a 
graphic display of the mean differences. 
 
  
* statistically significant differences between the groups at the p <.05 level 
Figure 5. Mean emergency room usage by comorbidity status 
 
The third question related to which comorbidities best predict emergency room 
utilization. Specific comorbidities that were examined included arthritis, asthma, congestive 
heart failure, chronic obstructive pulmonary disease, depression, diabetes, hypertension, 
injuries, pain and renal failure. To examine this question, a Poisson regression was used to 
predict the dependent variable of emergency room visits by the predictor variables of the 10 
types of comorbidities. Overall, findings from the model with all ten predictors were 
statistically significant. Within the model, three of the predictors were significantly 
associated with elevated emergency room utilization: COPD (p = .000); hyperlipidemia (p = 
.029) and hypertension (p = .010).  
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Cancer Type 
The fourth question relates to how cancer diagnosis impacts emergency room usage. 
Given that there were so many cancer types with very small sample sizes, a new variable was 
created that had the top three most common cancer types (i.e., breast cancer, lung cancer and 
gynecological cancers) with the remaining diverse cancers being grouped into an “other” 
category. A one way ANOVA was run to examine differences between these four groups in 
terms of emergency room usage. Overall, there were differences between the groups, F(198, 
3) = 4.53, p = .004. Post hoc analyses indicated that there were significant differences 
between two groups: individuals with a breast cancer diagnosis have significantly fewer 
mean emergency room visits (M = 0.74, SD = 1.95) than individuals in the diverse “other” 
category (M = 1.79, SD = 2.25), p = .013. While patients with lung cancer had the greatest 
mean emergency room utilization, the small sample size possibly impacted the ability to 
show statistically significant differences between other groups. See Figure 6 for a graphic 
display of the differences. 
   * statistically significant differences between the groups at the p <.05 level 
Figure 6. Mean emergency room usage by cancer diagnosis 
Insurance 
The final research question addressed whether insurance status is associated with 
emergency room utilization rates. A one-way ANOVA was used to explore this question, 
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with an independent variable of insurance status with participants being grouped into those 
who have commercial insurance, public insurance or other payment (i.e., unknown, self-pay 
or charity), and a dependent variable of number of emergency room encounters. The overall 
ANOVA was significant, F(196,2) = 11.1, p < .001. Post hoc analyses revealed differences 
between individuals who have public insurance (N = 83) and the two other groups, with 
individuals who have public insurance having a significantly higher mean number of 
emergency room visits (M = 2.06, SD = 2.6) than patients who have private insurance (N = 
79), (M = 0.62, SD = 0.9) (p <.001) and individuals (N = 37) in the “other payment” group 
(M = 1.62, SD = 1.9) (p = .03). There was not a statistically significant difference in 
emergency room utilization between those with public insurance and those in the other 
payment category (p = 0.5). See Figure 7 for a graphic display of the mean differences. 
 
 
   
Figure 7. Mean emergency room usage by insurance status 
Discussion 
For this project, three of the 10 essential public health services were used to ascertain 
what level of care cancer patients are receiving at the Providence Alaska Medical Center and 
how that care can be improved. The three essential services include monitoring, 
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may be possible to determine if the implementation of a PCMH model would better assist 
patients at PACC.  
Based on the results, there are several interesting findings with regard to factors that 
impact emergency room utilization rates for cancer patients. Interestingly, in this sample, 
patients who have a primary care physician have higher emergency room utilization rates 
than patients who do not have a primary care physician. The causal mechanism that produces 
this relationship is unknown. It is possible that patients who have a primary care physician 
are given guidance from this PCP in order to seek needed intervention, whereas patients who 
do not have a PCP who might experience the same symptoms but do not have the medical 
guidance, do not seek treatment for those same symptoms. Other variables could control the 
relationship as well. For instance, patients in this sample who have a PCP have a 
significantly higher number of comorbidities (M = 1.46, SD = 1.4) compared to patients who 
do not have a PCP (M = 0.61, SD = 0.99), t(54.3) = 4.09, p <.001. Therefore, perhaps 
comorbidities explain this relationship, with people with more health complications being 
more likely to seek regular emergency room treatment. However, this relationship too could 
be not entirely accurate. Perhaps individuals who regularly see a PCP will have their health 
status, including their comorbidities, entered into their health record, whereas patients 
without a PCP might have similar health concerns, but they are not adequately documented 
due to the lack of medical checkups. Another possibility that may help explain why cancer 
patients with PCPs utilized the Providence emergency room more than cancer patients 
without PCPs could be geographical. Cancer patients living in outlying areas close to the 
Municipality of Anchorage who experience a medical emergency might not use the 
Providence Emergency room, due to factors such as proximity; instead those patients are 
more likely to use Matsu Regional Hospital or other closer hospitals. This factor would not 
be captured by these data and would present an inaccurate breakdown of patient emergency 
room utilization. This possibility therefore might explain why our results do not parallel 
current literature. Future studies are needed in order to verify this finding and examine 
factors that influence it.  
 Comorbidities appear to greatly impact cancer patients’ medical treatment. Not 
surprisingly, patients who have more complicated medical needs (i.e., greater number of 
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comorbidities) utilize the emergency room more than patients with less complicated medical 
needs. Interestingly, some comorbidities are better predictors of patients seeking medical 
treatment than other comorbidities. Specifically, patients who experience COPD, 
hyperlipidemia and hypertension are more likely to seek emergency room treatment. In a 
patient centered medical model, these patients could benefit from more specific treatment 
plans outlining their medical care.  
 With regard to cancer type, there is an interesting finding pertaining to patients with 
breast cancer utilizing the emergency room less than patients who are in the “other” cancer 
diagnosis category. Breast cancer patients represented 27% of the random sample compared 
to 14%, which is the national average of cancer patients. This is most likely due to breast and 
gynecologic surgeons using PAMC. Given the high rates of breast cancer, the Providence 
Cancer Center has several support services particular to this cancer group. While breast and 
gynecologic cancer patients utilize the emergency room less frequently when compared to 
other groups, the underlying mechanism remains unknown. There could be a difference 
between comorbidities within the breast and gynecologic cancer populations compared to the 
lung and other cancer populations. For instance, breast cancer patients may have healthier 
lifestyle choices compared to individuals with lung cancer, which is a cancer that has a lot of 
lifestyle risk factors such as smoking. Interestingly, lung cancer patients had the highest 
emergency room utilization (M = 1.96, SD = 1.9), but given their low sample size (N = 26), it 
is likely that there was not enough statistical power to examine differences between this 
group and the other cancer groups. This finding possibly points to this cancer group in 
particular having a high need for medical services, and thus might especially benefit from 
more coordination in care. However, this result, since it is based on a small sample size, 
might not be representative for all patients who experience lung cancer.  
 In the analysis of data on insurance type, it was revealed that patients with public 
insurance were more likely to use the emergency room than patients with commercial 
insurance. Several reasons may account for this finding; one such reason for the difference 
could relate to age. Individuals in this sample with commercial insurance were younger (M = 
56.5, SD = 13.2) whereas individuals with public/federal insurance were older (M = 69, SD = 
15.9), t(161) = -5.47, p <.001. Comorbidity prevalence increases with age. Perhaps age better 
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accounts for the increase in emergency room utilization rates than insurance status alone. 
During the analysis of insurance type, population sizes were not large enough to determine if 
there was a difference between Medicare patients (N = 57) and Medicaid patients (N = 15) 
with regard to emergency room usage. If there was a difference between patients with 
Medicare and patients with Medicaid, this information would be helpful to the state in 
helping increase preventative efforts for those patient populations in order to drive down 
future healthcare costs. As with the primary care physician status, perhaps comorbidities 
explain this relationship as well. For instance, patients in this sample who have federal 
(public) insurance have a significantly higher number of comorbidities (M = 1.85, SD = 1.4) 
compared to patients who have private insurance (M = 1.05, SD = 1.2), t(161) = -3.94, p 
<.001.   
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Chapter 8: Strengths and Limitations 
Strengths 
 There are a few strengths that are particular to this study. First, this study utilized data 
from an electronic medical record, which allows for better data capture and collection. This 
strength also ties into lower costs for research studies such as this. Also data collection of this 
nature is typically easier to analyze. In addition, the setup of Alaskan healthcare possibly 
allowed for greater accuracy in the data collection, since PAMC is one of three major 
healthcare resources within the Anchorage area and PAMC has the only designated cancer 
center within the state. Another strength of this study was the support from the Providence 
Cancer Center Medical Director, as well as the Cancer Center staff. With their support, 
access to information in order to carry out this study was a smooth process.  
Limitations 
 As with any study, there are several limitations. One limitation relates to the limited 
information related to seeking medical treatment. Originally, this study hoped to examine 
multiple types of treatment, including emergency room visits, hospital admissions and 
hospital re-admissions. Given the difficulty in collecting the hospital admission and re-
admission information from the medical record (with having to go through each individual 
patient encounter), only emergency room visits were able to be examined, which gives a 
limited picture of patient medical treatment. In addition, the reasons for emergency room 
visits was not able to be documented, which could have helped to illuminate other factors 
that relate to cancer patients medical treatment.  
 Another limitation mentioned previously related to the documentation of 
comorbidities. It is possible that some comorbidities, especially for individuals who did not 
have a primary care physician, might be present but not reflected in the medical record due to 
physician error or the patient not being seen regularly to be assessed. For example, the 
second most common comorbidity in this study (depression) is commonly under diagnosed, 
especially in medical settings (Mojtabai, 2014). If comorbidities are not accurately and 
consistently being assessed and/or documented in the medical record, then the relationships 
identified between different types of comorbidities and patient medical treatment might be 
inaccurate.  
32 
 
 The smaller sample sizes for some of the comorbidities could be another limiting 
factor. All of the comorbidities except one (hypertension) had a sample size below 40. These 
low numbers may have made it difficult to examine specific relationships between individual 
comorbidities and emergency room usage. This analysis was added after the initial power 
analysis. The power analysis was not redone. Even if the power analysis had been redone it 
would be likely that a much larger data sample would be required, which would be 
logistically impractical due to time constraints, need to get renewed IRB approval and 
practical limitations based on the initial size of cancer patients seen at the PACC.  
With regard to categorizing patients who had a primary care physician, we were also 
unable to examine the last time the patient actually saw the PCP to verify that they had an 
active primary care physician. In one study by Chaiyachati et al. (2014), data analysis 
showed that patients who had seen their PCP within the last year were less likely to use the 
emergency room. Having this data on the last visit with a PCP might have made it possible to 
more accurately categorize patients who are actively seeing a PCP and those who are not.  
Another limitation of this research project was determined that the sampling frame 
was too broad This limitation was only found out after the data analysis. Though the 
literature supports lower emergency room utilization by patients with current PCPs, this 
project found did not support that finding. In trying to determine why, the observation was 
made that a large number (90 patients) did not utilize the emergency room. As was 
mentioned early in this paper, Alaska is a large state with a lot of geographical variation. 
While these patients may have been seen at PAMC for cancer services, that does not mean 
they utilized PAMC for all services. If a patient lived in a different part of the state, they may 
have utilized other hospitals resources and that data would not have been collected during 
this study. By not selecting the sample based on patients who would utilize services within 
the Anchorage area, and PAMC in particular, patients were introduced to the sample who 
were impossible to collect accurate medical data on. Because of this, data such as emergency 
room usage might not be entirely accurate.  
In examining the results of this study, it is important to remember that given that this 
study examined a single time point, some dynamic relationships such as causal temporal 
relationships cannot be verified. Some of the relationships in the data that were found may 
33 
 
have been pre-existing prior to specific factors such as cancer diagnosis or development or 
specific comorbidities.  In addition, given the small sample sizes in some groups, such as the 
number of patients with lung cancer, it is possible that segments of the sample size, or even 
the whole sample size of 200 patients, still might not be representative of all the 1200 PACC 
cancer patients, despite the use of random selection. 
A final point of consideration is whether the data is clinically significant or not. Since 
the data set is not as specific as needed to make more accurate suggestions that could then go 
on to impact patient care, then this data is not clinically significant. With future research and 
further refinement of the research questions regarding patients with PCPs and emergency 
room utilization, future data that is clinically significant may be ascertained; but at this time, 
this data shows that there are interesting trends occurring at PACC and that future 
investigation should be considered. 
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Chapter 9: Future Directions 
Plans for Dissemination 
 There are a number of plans for dissemination of this project in order to fulfill the 
requirements of a project practicum and to meet the needs and wishes of the Providence 
Cancer Center. In terms of requirements for the UAA Masters of Public Health Project 
Practicum, results will be disseminated through an oral presentation of this project practicum 
to the project committee, the University of Alaska Anchorage faculty, and general public.  
Additional plans for dissemination have been made to address the needs of the 
Providence Alaska Cancer Center. A presentation to the Providence Cancer Committee 
during one of their quarterly meetings will occur in order to present the findings. Following 
the initial presentation of the data, the Cancer Committee will discuss how to utilize these 
findings at the PACC. Dr. Mego and the Providence Cancer committee will determine 1) 
what additional data they may need to investigate in order to develop a more complete 
picture of the need and potential use of a PCMH model and 2) whether a PCMH model is 
desirable and feasible for cancer patients at Providence Alaska Medical Center. Additionally, 
Dr. Mego could present the findings to the Providence Alaska Cancer Center executive 
leadership in order to get broader support for additional research and/or changes in the PACC 
in order to adopt a PCMH model.  
 Plans for Future Studies 
As this study was a preliminary examination into the developmental needs of a 
possible Patient Centered Medical Home at the Providence Alaska Cancer Center, additional 
information will likely be needed based on feedback and questions from the PAMC Cancer 
Committee and PAMC Cancer Center leadership. Future MPH students in conjunction with 
Dr. Mego and the Providence Alaska Cancer Center could conduct further research directed 
towards implementation of a PCMH model or other model of coordinated care, as well as 
participate in future program evaluation. 
A potential area of future research could be to further explore why patients with PCPs 
in this sample seemed to have higher emergency room utilization. To answer this question, 
information would need to be gathered from patients and their primary care physicians, and 
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there needs to be a more detailed analysis of the encounter notes for each emergency room 
visit, in order to determine the reason why patients with a PCP seem to be utilizing the 
emergency room at a greater rate. Currently, there is limited research in regards to if there is 
a difference in how urban patients utilize the emergency room versus rural patients. The 
limited literature does suggest that patients living outside an urban area are more likely to 
utilize the emergency room than patients living in an urban area (Gindi, Cohen & Kirzinger, 
2012). In order to get a better understanding of ER utilization by cancer patients seen at the 
PACC, a future investigator should structure their study to capture all ER visits by the cancer 
patients, and not be limited to identification of PAMC ER visits. This could be done best by 
interviewing cancer patients and providers in the future to get a better understanding of true 
emergency room utilization rates among cancer patients at the PAMC and to determine the 
factors leading to emergency room utilization.  
It should also be determined how active a patient is with their PCP, e.g. when a 
patient last had an appointment with their PCP. If the patient has a PCP listed but has not 
actually seen the PCP within the last year, this needs to be taken into consideration. Current 
literature indicates that frequency of visiting a PCP impacts ER utilization rates, but this 
relationship could not be verified with this data and with this patient population (Chaiyachati 
et al., 2014). This information could have implications for how often patients visit their PCP, 
should PACC utilize a PCMH model. For instance, if the high utilizers of the emergency 
room were found to not regularly see their PCP despite having an active one listed, then 
additional interventions could be used in order to increase their motivation and ability (i.e. 
through taxi vouchers, etc.) to regularly see their PCP.  
Determining which cancer patients utilized the emergency room is also important. In 
one study fever, shortness of breath and pain were common ailments for cancer patients 
admitted to the emergency room (Sadik et al., 2014). In the same study, it was observed that 
approximately half of lung cancer patients that utilized the emergency room had passed away 
after their first emergency room utilization. This result implies that emergency room 
utilization is a poor prognostic factor for lung cancer patients. Along a similar line, 
determining if the patient was admitted to the hospital after being admitted to the emergency 
room as well as when the patient was discharged would be interesting data to help determine 
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hospital resource utilization and patient outcome. This data may help to refine care of cancer 
patients. Cancer patients just like any patient and are not two-dimensional in behavior. A 
future study should also look at what stages of cancer treatment patients are utilizing the 
emergency room. Using EPIC, future research could determine when the initial diagnosis of 
cancer was made and then determine not only how often emergency room utilization 
occurred, but the frequency of emergency room visits after the initial diagnosis. This may aid 
healthcare providers in being more aware of cancer patient behaviors when determining 
emergency room utilization, and could help inform intervention plans for patients at different 
points in treatment. One retrospective study, that observed 113 cancer patients found that as 
cancer stage increased so did emergency room utilization (Kotajima, Kobayashi, Sakaguchi, 
& Nemoto, 2014). 
Another area of interest will be to increase the sampling size in order to determine if 
cancer patients with Medicare versus Medicaid versus Veteran’s Affairs utilize the 
emergency room more often or not. This analysis could not be run during this project based 
on the small Medicaid population in the sample. If it was found that Medicaid patients used 
the emergency room more often, then this might lead to an increased state effort to help with 
the implementation of a PCMH model in order to increase state savings by potentially 
reducing emergency room utilization.  
As was mentioned earlier in this paper, medical practices transitioning to a PCMH 
model are not able to just flip a switch and convert over to that model of patient care; 
significant time, money, resources and a proper implementation strategy are all required for 
success. Future research should be devoted to further characterize the needs of the PAMC 
cancer patient population to determine how best to utilize the resources available to the 
PACC to implement a coordinated care model, and what that coordinated care model should 
look like.  
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